microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers

Oncotarget

Volumn 5, Issue 5, 2014, Pages 1174-1184

  Gasparini, Pierluigi ^a   Cascione, Luciano ^a,h   Fassan, Matteo ^a,b   Lovat, Francesca ^a   Guler, Gulnur ^c   Balci, Serdar ^d   Irkkan, Cigdem ^e   Morrison, Carl ^f   Croce, Carlo M ^a   Shapiro, Charles L ^g   Huebner, Kay ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^c HACETTEPE UNIVERSITY   (Turkey)

^d YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

^e MINISTRY OF HEALTH   (Turkey)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h InstituteofOncologyResearch   (Swaziland)

Author keywords

Five markers; Microrna; Outcome; Prognosis; Treatments; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MICRORNA; MICRORNA 155; MIR 27A; MIR 30E; MIR 493; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; MIRN155 MICRORNA, HUMAN; MIRN27 MICRORNA, HUMAN; MIRN30 MICRORNA, HUMAN; MIRN493 MICRORNA, HUMAN; TAXOID; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; CHEMISTRY; DNA MICROARRAY; DOWN REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; UPREGULATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOWN-REGULATION; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-5; KERATIN-6; METHOTREXATE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SURVIVAL RATE; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84896949069     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1682     Document Type: Article

References (45)

1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011; 121(7):2750-2767.
2. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS medicine. 2010; 7(5):e1000279.
3. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(5):1368-1376.
4. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI and Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. The Journal of pathology. 2004; 203(2):661- 671.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA : the journal of the American Medical Association. 2006; 295(21):2492-2502.
6. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(16):5367-5374.
7. Prat A and Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular oncology. 2011; 5(1):5-23.
8. Nielsen JS, Jakobsen E, Holund B, Bertelsen K and Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2004; 14(6):1086-1096.
9. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer research. 2006; 66(16):8163-8171.
10. Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP. The impact of microRNAs on protein output. Nature. 2008; 455(7209):64-71.
11. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-233.
12. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer journal. 2010; 16(1):53-61.
13. Joerger M and Thurlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert review of anticancer therapy. 2013; 13(2):165-178.
14. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. The oncologist. 2011; 16 Suppl 1:71-78.
15. Irshad S, Ellis P and Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current opinion in oncology. 2011; 23(6):566-577.
16. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Jr., Ellis P, Di Leo A, Baselga J, Sotiriou C and Piccart-Gebhart M. Dissecting the heterogeneity of triple-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30(15):1879- 1887.
17. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL and Huebner K. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PloS one. 2013; 8(2):e55910.
18. He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP and Chang HR. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. International journal of proteomics. 2011; 2011:896476.
19. Hendrix MJ, Seftor EA, Seftor RE and Trevor KT. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. The American journal of pathology. 1997; 150(2):483-495.
20. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M. Vimentin and epithelialmesenchymal transition in human breast cancer-- observations in vitro and in vivo. Cells, tissues, organs. 2007; 185(1-3):191-203.
21. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W and Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? The Journal of pathology. 2005; 206(4):451-457.
22. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell cycle. 2005; 4(12):1693-1698.
23. Huff CA, Matsui W, Smith BD and Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006; 107(2):431-434.
24. Velasco-Velazquez MA, Homsi N, De La Fuente M and Pestell RG. Breast cancer stem cells. The international journal of biochemistry & cell biology. 2012; 44(4):573- 577.
25. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M and Isola J. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast cancer research : BCR. 2007; 9(1):R16.
26. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO and Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC cancer. 2007; 7:134.
27. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J and Safe S. MicroRNA-27a Indirectly Regulates Estrogen Receptor {alpha} Expression and Hormone Responsiveness in MCF- 7 Breast Cancer Cells. Endocrinology. 2010; 151(6):2462- 2473.
28. Tang W, Zhu J, Su S, Wu W, Liu Q, Su F and Yu F. MiR- 27 as a prognostic marker for breast cancer progression and patient survival. PloS one. 2012; 7(12):e51702.
29. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S,Heerema N and Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)- miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(18):7024-7029.
30. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, Costinean S, Sandhu SK, Nuovo GJ, Alder H, Gafa R, Calore F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(15):6982-6987.
31. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J and Li J. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PloS one. 2012; 7(10):e47003.
32. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth- Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2013.
33. Lyng MB, Laenkholm AV, Sokilde R, Gravgaard KH, Litman T and Ditzel HJ. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PloS one. 2012; 7(5):e36170.
34. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D and Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23(9):2223-2234.
35. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR and Smith IE. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. Journal of clinical pathology. 2006; 59(7):729-735.
36. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(36):5652- 5657.
37. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J and Palacios J. Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(5):1533-1539.
38. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J and Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131(6):1109-1123.
39. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer cell. 2004; 5(1):13-17.
40. Usami Y, Satake S, Nakayama F, Matsumoto M, Ohnuma K, Komori T, Semba S, Ito A and Yokozaki H. Snailassociated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. The Journal of pathology. 2008; 215(3):330- 339.
41. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011; 30(12):1436-1448.
42. Guler G, Balci S, Costinean S, Ussakli CH, Irkkan C, Suren D, Sari E, Altundag K, Ozisik Y, Jones S, Bacher J, Shapiro CL and Huebner K. Stem cell-related markers in primary breast cancers and associated metastatic lesions. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012; 25(7):949-955.
43. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger- Saal SK, Lovgren K, Grabau D, Ferno M, Borg A and Hegardt C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast cancer research : BCR. 2008; 10(3):R53.
44. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ and Tuschl T. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer research. 2011; 71(13):4443-4453.
45. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.